
















































Autoimmune diseases are a clinically diverse group of 
complex disorders such as type 1 diabetes mellitus 
(T1D), multiple sclerosis (MS), Graves’ disease (GD), 
Crohn's  disease,  rheumatoid  arthritis  (RA),  psoriasis,  
 
 















































systemic lupus erythematosus (SLE), etc. In total, they 
affect 5-7% of the world population [1]. Autoimmune 
diseases occur as a result of the loss of physiological 
tolerance to self antigens and are characterized by 
persistent activation of immune cells, leading to tissue 
















































findings  provide  further  evidence  that  the  PTPN22  gene  may  play  an  important  role  in  the  susceptibility  to  some
autoimmune diseases.  
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regulating the extent of immune response.  Major 
histocompatibility complex (MHC), especially MHC 
class II, has the most potent genetic influence on 
susceptibility to autoimmune disease [1, 3] . Among 
multiple non-HLA genes involved in autoimmunity 
regulation, cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) [4-7], tumor necrosis factor (TNF) [3, 8] and 
protein tyrosine phosphatase nonreceptor 22 gene 
(PTPN22) are the most important.  
 
The PTPN22 gene is located on chromosome 1p13 and 
encodes a lymphoid protein tyrosine phosphatase (LYP) 
that is important in negative control of T-cell activation 
and in T-cell development. PTPN22 belongs to a family 
of protein tyrosine phosphatases involved in preventing 
spontaneous T-cell activation by dephosphorylation and 
inactivation of T-cell receptor-associated kinases and 
their substrates [9, 10]. PTPN22 is specifically 
expressed in lymphocytes [11] and through formation of 
a complex with C-terminal Src Kinase (CSK) 
suppresses the downstream mediators of T-cell receptor 
signaling [12, 13]. Earlier, PTPN22 gene was found to 
be associated with susceptibility to T1D [14]. Later it 
was shown that several SNPs could potentially 
contribute to susceptibility to various autoimmune 
disorders. Among them 1858C/T SNP was the most 
stable , where T allele correlated with T1D, RA, SLE, 
GD, Addison disease, etc [15-20]. However, the data 
varied from population to population and some studies 
failed to demonstrate any associations between   
1858C/T SNP and autoimmune diseases. 
 
Using a conventional approach, we performed a case-
control association study between 1858C/T 
polymorphism and type 1 diabetes, RA and Graves’ 
disease in a Russian population. 
 
PATIENTS AND METHODS 
 
Patients. All patients and control subjects were from the 
North-West region of  Russia. The study was performed 
after written inform consent and was approved by the 
Ethic committee from each institute and hospital 
participating in the study: Almazov Federal Heart, 
Blood and Endocrinology Centre, Saint-Petersburg 
Diabetology Center №1. 
 
T1D. The diagnosis was established before the age of 
20 years, using following criteria (defined by the 
National Diabetes Data Group): blood glucose level, 
presence of ketosis at onset, low body mass index and 
the need for insulin treatment. The diagnosis of T1D 
was confirmed by the presence of at least one of the two 
major antibodies: GAD65 antibodies, and/or anti-
tyrosine phosphate like molecule (ICA512) antibodies. 
 
RA. Patients with 1 to 34 year-lasting (average of 
12,524±4,982 years) disease were included in the study, 
of which 87% were rheumatoid factor seropositive.  
 
GD. Patients with 1 to 15 year-lasting Graves’ disease 
participated in the study. The diagnosis was confirmed 
by the presence of thyrotoxicosis (increased levels of 
free triiodothyronine, free thyroxine , thyroid-
stimulating hormone (TSH) <0,1 mMU/l) associated 
with diffuse hyperfunctional goiter other autoimmune 
manifestations (Graves' ophthalmopathy) and/or 
increased level of TSH receptor antibodies. 
  
Healthy control subjects had normal glucose tolerance 
and no family history of autoimmune diseases. Genomic 
DNA was isolated from the peripheral blood sample 
using a phenol-chloroform  extraction method [21]. The 
study included 150 patients with T1D, 171 patients with 
GD, 121 patients with RA and 200 healthy donors.  
 
Genotyping was performed by PCR-restriction fragment 
length polymorphism (RFLP) method. A region of the 
PTPN22 gene (218-bp) containing the C1858T SNP 
(R620W) was amplified by the PCR using genomic 
DNA.  The sequence-specific primers used were: 
forward 5`-ACTGATAATGTTGCTTCAACGG-3` and 
reverse 5`-TCACCAGCTTCCTCAACCAC-3’[22]. 
Each 25-μl amplification reaction contained  2 μl (20-30 
ng) of DNA, 2.5 μl 10 x PCR buffer, 200 μM dNTPs, 2 
mM MgCl2, 200 nM of each primer and 2.5 U Taq 
polymerase. The PCR began with an initial denaturation 
at 94°C for 5 minutes, followed by 30 cycles consisting 
of 30 sec at 94°C, 60 sec at 62°C, and 60 sec at 72°C, 
and it ended with a final elongation step at 72°C for 5 
minutes. Amplified products were digested using RsaI 
(SibEnzyme) overnight at 37°C. Digested products were 
electrophoresed on a 3% agarose gel and visualized by 
ethidium bromide. RsaI recognizes its target sequence 
only when the PTPN22 1858C allele is present. The 
1858T allele is not digested and yields one fragment of 
218 bp, while the 1858C allele is digested and yields 
two fragments of 176 bp and 46 bp. 
 
Statistical analysis.  Data obtained for patients and 
controls were compared using Chi-square testing and 
Fisher exact test. All calculations were performed using 




The genotype and allele frequencies are presented in 
Table 1. Distribution of genotypes was consistent with 
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and in the control group.  
 
The case-control study showed that the distribution of 
the PTPN22 1858C/T SNP genotypes differ 
significantly between T1D patients and healthy 
controls, and between GD patients and healthy controls. 
The disease-associated homozygous genotype T/T has 
an increased frequency in T1D and GD patients vs. 
control subjects:  7%  and  4.1%  vs.  1%,   respectively  







        
 
     
 
 

































P<0.05, OR 4.23 (95% CI 0.87-20.62) for GD). 
However, there was no statistically significant 
association between T allele and these disorders. This 
observation can be partially explained both by the 
complexity of statistical analysis in small populations 
per se, and with low overall allele frequencies, as 
observed for PTPN22 gene polymorphism. 
 
In the group of RA patients, no statistically significant 
difference was detected in a distribution of genotypes or 
























































T/T  2 (1)  11 (7)  7 (4)  2 (2) 
C/T  66 (33)  40 (27)  49 (29)  38 (31) 
C/C  132 (66)   99 (66)  115 (67)  81 (67) 
P -  <0.001  <0.05 NS 
c 
OR (95% CI) 
b 
-  7.84 (1.71-35.90)  4.23 (0.87-20.62)  3.50 (0.74-16.70) 
Allele T  70 (17.5)  62 (20.5)  63 (18)  42 (17) 
Allele C  330 (82.5)  238 (79.5)  279 (82)  200 (83) 
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1858C/T SNP is located in the N-terminal proline-rich 
motif of PTPN22 and leads to the substitution of 
arginine with tryptophan at codon 620 in lymphoid 
protein tyrosine phosphatase. The 1858T allele (variant 
620W) of PTPN22 is a gain-of-function form of the 
enzyme, thus it results in an increased inhibition of 
TCR-mediated signals [23]. In vitro studies showed that 
the disease-associated LYP variant 620W prevents the 
interaction of LYP with CSK [15]. The CSK-LYP 
complex normally suppresses T cell receptor signaling 
kinases Lck, ZAP-70 and FYN. However, in the 
presence of mutant 620W form of LYP, lack of CSK-
LYP interaction leads to the uncontrolled T cell 
induction and results in the increase in overall reactivity 
of the immune system [24]. Disruption of mouse 
ortholog of the human PTPN22 gene resulted in 
elevated serum antibody levels and increased memory T 
cells number, which are able to aggravate any 
autoimmune process [19, 25]. 
 
Numerous studies revealed the correlation between 
1858C/T SNP with RA [15,  16,  26-28], SLE [17, 29], 
T1D [14, 18, 30], GD [18, 19], Myasthenia Gravis [31], 
WG [32] etc. However, this association may be 
questionable for some of these diseases, such as SLE 
and RA, as a number of studies failed to demonstrate it 
[33, 34]. At the same time, no association with multiple 
sclerosis (MS) [35, 36], Crohn's disease [37-39], 
ulcerative colitis [39], psoriasis and psoriatic arthritis 
[36] was found so far. 
 
In compliance with other authors we demonstrated a 
significant association between PTPN22 1858 C/T SNP 
and T1D and GD. As many autoimmune disorders T1D 
and GD are associated with abnormal activation of 
immune system, which results in damage of organs and 
tissues. T1D is characterized by autoimmune 
destruction of insulin-producing β-cells in the pancreas. 
GD is an organ-specific autoimmune thyroid disorder 
characterized by hyperthyroidism, various degrees of 
diffuse goiter and ophthalmopathy. Genetic 
susceptibility is important in the development of both 
disorders. Over the last three decades, the study of T1D 
has led the field in the identification of genes 
underlying complex multifactorial diseases. Besides 
HLA class 2 genes, gene encoding insulin, CTLA4 and 
interleukin-2 receptor alpha (IL2RA) genes, PTPN22 
presumably contributes to T1D susceptibility [14, 18, 
30,  40, 41]. GD was also reported to have a substantial 
genetic component [7, 19, 42].  
 
In contrast to our data for T1D and GD, the association 
between PTPN22 1858C/T and RA could not be 
verified in our study.  This may be explained by the 
variation in PTPN22 allele frequencies in different 
ethnic groups, as described by Mori et al [43]. 
According to the available data on PTPN22 allele 
frequencies distribution worldwide, the degree of the 
association between 1858C/T SNP and different 
autoimmune diseases is variable among ethnic 
populations, suggesting that 1858C/T SNP may be of 
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